# NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-full-year-2025-financial-results-and-provides-corporate-update
Ticker: NAMS
Company: NewAmsterdam Pharma
Source: NewAmsterdam Pharma
Published: 2026-02-18 12:01 EST
Original Source URL: https://ir.newamsterdampharma.com
## Summary

-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY--          -- Topline data from RUBENS Phase 3 tria

## Article Body
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY--          -- Topline data from RUBENS Phase 3 trial in
## Recent Company News
- 2026-07-29 12:00 EST — [NewAmsterdam Pharma to Host Investor Day on August 5, 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-host-investor-day-on-august-5-2026-00cdef02) — Source: NewAmsterdam Pharma
- 2026-07-24 12:00 EST — [NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-and-menarini-group-receive-positive-chmp-opinion-recommendin-6e39bfc3) — Source: NewAmsterdam Pharma
- 2026-07-02 20:01 EST — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3a377d4b) — Source: NewAmsterdam Pharma
- 2026-07-01 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-associat-5f8e7eb9) — Source: NewAmsterdam Pharma
- 2026-06-03 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-national-lipid-association-nla-2026-scientific-sessions) — Source: NewAmsterdam Pharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)